A5059760177- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Blood groups and transfusion
- Venous Thromboembolism Diagnosis and Management
- Osteoarthritis Treatment and Mechanisms
- Chronic Lymphocytic Leukemia Research
- Blood properties and coagulation
- Atrial Fibrillation Management and Outcomes
- Cancer Genomics and Diagnostics
- Protease and Inhibitor Mechanisms
- Antifungal resistance and susceptibility
- Cancer-related gene regulation
- Maternal and fetal healthcare
- Autoimmune Bullous Skin Diseases
- Autoimmune and Inflammatory Disorders Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Dialysis and Renal Disease Management
- Parvovirus B19 Infection Studies
- Acute Lymphoblastic Leukemia research
- Infectious Diseases and Mycology
Máxima Medisch Centrum
2018-2025
Radboud University Nijmegen
2018-2025
University of Amsterdam
2024
Amsterdam University Medical Centers
2024
Hersenstichting
2023
Leiden University Medical Center
2023
Erasmus MC - Sophia Children’s Hospital
2022
Erasmus MC
2020
University Medical Center Utrecht
2012-2015
Heidelberg University
2013-2014
Background Treatment of patients with hemophilia has advanced over the past decades, but it is unknown whether this resulted in a normal life expectancy Netherlands. Objective This observational cohort study aimed to assess all-cause and cause-specific mortality Netherlands between 2001 2018 compare previous survival assessments from 1973 onward. Patients/methods All 1066 who participated nationwide survey were followed until July 2018. Results Information on 1031 individuals (97%) was...
BackgroundIn recent years, more awareness is raised about sex-specific dilemmas in inherited bleeding disorders. However, no large studies have been performed to assess differences diagnosis, phenotype and management of men women with Therefore, we investigated sex a cohort well-defined patients autosomal disorders (von Willebrand disease (VWD), rare (RBDs) congenital platelet defects (CPDs)).MethodsWe included from three nationwide cross-sectional on VWD, RBDs CPDs the Netherlands,...
Summary Recurrent joint bleeding is the most common manifestation of severe haemophilia resulting in haemophilic arthropathy ( HA ). Iron plays a central role pathogenesis two main features : synovitis and cartilage destruction. The aim this study was to investigate synovial presence iron regulator proteins ferroportin FPN ), hepcidin, haemoglobin scavenger receptor CD 163 163), feline leukaemia virus subgroup C FLVCR heme carrier protein 1 HCP ‐1). A comparison expression with rheumatoid...
Abstract Patients with hereditary rare bleeding disorders (RBDs) present diverse hemorrhagic symptoms. Correlation between factor activity levels and clinical severity is poor for most RBDs. Threshold have been previously described in relation to but not yet validated. The Rare Bleeding Disorders the Netherlands (RBiN) study a nationwide cross-sectional of patients registered all 6 Dutch Haemophilia Treatment Centers known RBD who are age 1 99 years. scores were determined, laboratory data...
Limited data exists on persons with rare bleeding disorders (RBDs) possessing a heterozygous genotype, as most studies focus bi-allelic genotypes and more severe coagulation factor deficiencies. A growing body of evidence suggests that genotype experience clinically relevant symptoms. Explore the incidence symptoms postoperative in genotype. This cross-sectional sub-study Rare Bleeding Disorders Netherlands study (2017-2019) included deficiencies fibrinolysis or Clinical laboratory samples...
Congenital fibrinogen disorders (CFDs), encompassing quantitative (hypo-/afibrinogenemia) and qualitative (dysfibrinogenemia) defects, can result in bleeding or thrombotic events. This study aimed to enhance understanding of the clinical genetic characteristics CFD patients. The Dutch cross-sectional RBiN included 47 patients (median age 38, 55 % women), categorized into (hypo)dysfibrinogenemia, severe (<500 mg/L), moderate (500-1000 mg/L) mild hypofibrinogenemia (1000-1800 as well carriers...
The risk of relapse among high-risk diffuse large B-cell lymphoma (DLBCL) patients in complete metabolic remission (CMR) following R-CHOP therapy is 20-25%. Here, we evaluated whether consolidation with the PDL-1 checkpoint inhibitor atezolizumab could reduce risk. In this phase II, open-label trial (NCT03463057) DLBCL an international prognostic index (IPI) score ≥ 3 and CMR after received 1200mg every weeks for 18 cycles. primary endpoint was disease-free survival (DFS) at 2 years aim...
The combination of interleukin (IL)-4 and IL-10 protects against blood-induced cartilage damage in vitro. It has been hypothesized that the these cytokines is effective if applied early process damage. present study investigated whether a single intra-articular injection IL-4 plus immediately after joint bleed limits an vivo haemophilia mouse model Factor VIII knockout mice with severe A were punctured once needle below patella to induce haemorrhage. Subsequently (n = 24) or vehicle was...
Summary Recurrent joint bleeding is the most common manifestation of haemophilia resulting in haemophilic arthropathy (HA). The exact pathophysiology unknown, but it suggested that stimulated by liberation fibrinolytic activators from synovium during haemarthrosis. aim this study was to test hypothesis haemarthrosis activates local synovial system a murine model. right knees and control mice were punctured induce left served as internal joints. Synovial levels urokinase-type plasminogen...
Analysis of fibrinolytic disorders is challenging and may potentially lead to underdiagnosis patients with an increased bleeding tendency.
Introduction Patients with bleeding disorders may experience limitations in sports participation and physical activity. Several studies on have been performed haemophilia patients, but patients von Willebrand disease (VWD) are lacking. Aim We assessed the activity of a large cohort VWD patients. Methods were included from “WiN study.” All completed questionnaire participation, activity, quality life symptoms (Tosetto score). Results From 798 474 had type 1, 301 2 23 3 VWD. The mean age was...
Joint bleeds in haemophilia result iron-mediated synovitis and cartilage damage. It was evaluated whether deferasirox, an iron chelator, able to limit the development of haemophilic Haemophilic mice were randomly assigned oral treatment with deferasirox (30 mg/kg) or its vehicle (control) mg/kg). Eight weeks after start treatment, haemarthrosis induced. After another five blood-induced damage determined. Treatment resulted a statistically significant (p< 0.01) decrease plasma ferritin levels...
In premenopausal women, treatment with direct oral factor Xa inhibitors is associated an increased risk of heavy menstrual bleeding (HMB) compared vitamin K antagonists (VKA). Treatment the thrombin inhibitor dabigatran appears to be a reduced HMB VKA. These findings come from small observational studies or post hoc analyses trials in which was not primary outcome. Use tranexamic acid during period may effective patients HMB, but prospective data regarding efficacy and safety on...